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276Abstract: Oxaliplatin is the standard treatment for advanced colorectal cancer. Its dose-limiting tox-
icity is the development of a painful neuropathic syndrome sustained by unclear mechanisms. Al-
though the oxidative hypothesis is a matter of debate, direct data about oxidative damage
induced in vivo by anticancer agents are lacking and the efficacy of the available antioxidant com-
pounds are unsatisfactory. In a rat model of painful oxaliplatin-induced neuropathy (2.4 mgkg1
i.p., daily for 21 days), we described an important component of oxidative stress. In the plasma of
oxaliplatin-treated rats, the increases in carbonylated protein and thiobarbituric acid reactive sub-
stances were the index of the resultant protein oxidation and lipoperoxidation, respectively. The
same pattern of oxidation was revealed also in the sciatic nerve, and in the spinal cord where the
damage reached the DNA level. The antioxidant compound silibinin (100 mgkg1 per os), adminis-
tered once a day, starting from the first day of oxaliplatin injection until the 20th, prevented oxida-
tive damage as did a-tocopherol. Repetitive administration of silibinin, as well as a-tocopherol,
reduced oxaliplatin-dependent pain induced by mechanical and thermal stimuli. Antioxidants were
also able to improve motor coordination. The antineuropathic effect of both molecules improved
by about 50% oxaliplatin-induced behavioral alterations.
Perspective: This study characterizes oxidative stress parameters in a rat model of oxaliplatin-
induced neuropathy. A relationship between the improvement of oxidative alterations and pain re-
lief is established in rats treated with natural antioxidant compounds like a-tocopherol and silibinin.
Silibinin could be a valid therapeutic option for chemotherapy-induced neuropathy.
ª 2012 by the American Pain Society
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xaliplatin is a platin-organic drug with anti-
neoplastic properties electively used for the treat-
ment of advanced colorectal cancer and a valid
option for patients in the adjuvant setting. Unlike other
platinum derivatives, its use induces only mild hemato-
logical and gastrointestinal side effects, and does not re-
sult in significant renal impairment or ototoxicity. The
dose-limiting toxicity of oxaliplatin is the development
of a neuropathic syndrome with paresthesia, dysesthe-
sia, and pain. A tangled panel of symptoms may be
disabling for treated patients, adversely affecting activi-August 30, 2011; Revised November 22, 2011; Accepted
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16/j.jpain.2011.11.009ties of daily living and thereby quality of life, until
suspension of the therapy.12,17,42 Whereas neuropathy
acutely developed is usually self-limiting, often resolving
the symptoms within days, repeated oxaliplatin adminis-
tration induces a chronic neuropathy that cannot be
resolved between cycles.3,9,14,17
Randomized trials demonstrating a prophylactic or
therapeutic effect of antihyperalgesic drugs on oxalipla-
tin’s cumulative neurotoxicity are still lackingor inconclu-
sive.2,24 Amongpharmacological treatments, antioxidant
compounds have been tested as possible therapeutic
approaches. In particular, glutathione, N-acetylcysteine,
and vitamin E (a-tocopherol) may have a clinical role in
patient neuroprotection.4,6,7,25,29,35 However, the major
bias of these clinical trials resides in their small size and/
or in their short term follow-up.2
An important limit in this field is the insufficient infor-
mation on the molecular basis of the neuropathy. De-
spite the empirical therapeutic use of antioxidants, the
oxidative hypothesis in oxaliplatin neurotoxicity is still
a matter of debate. In mouse hybrid neurons, Park
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vation of p53 signaling play a major role in cisplatin-
induced neuronal apoptotic cell death. Antioxidants as
N-acetylcysteine can reduce this apoptotic pathway at-
tenuating p53 accumulation.37 Moreover, glutathione-
inhibitable production of superoxide anion (O2
.) has
been described for oxaliplatin in CHO cells.34
As things stand today, direct data about oxidative
damage induced in vivo by platin derivatives are how-
ever still lacking. Moreover, the absence of a clear oxida-
tion target hampers the finding of more active
antioxidant compounds.
In order to directly evaluate the role of oxidative stress
in oxaliplatin neurotoxicity, we characterized the oxida-
tive profile of plasma and the nervous system in a rat
model of oxaliplatin-induced neuropathy. To study the
relationship between oxidative status and pain, a re-
peated treatment with the natural antioxidant com-
pound a-tocopherol was performed. Aimed to pinpoint
new potential antineuropathic treatments, we evalu-
ated the antihyperalgesic effect of silibinin, the principal
component of the silymarin complex, an active extract
from the seeds of the plant milk thistle (Silybum maria-
num). It has been shown that silibinin inhibits overpro-
duction of O2
. by stimulated neutrophils, xanthine
oxidase activity, and prevents hem-mediated oxidative
modification of low density lipoproteins.39,42Methods
Animals
For all the experiments described below, male
Sprague-Dawley rats (Harlan, Varese, Italy) weighing ap-
proximately 200 to 250 g at the beginning of the exper-
imental procedure were used. Animals were housed in
CeSAL (Centro Stabulazione Animali da Laboratorio,
University of Florence) and used at least 1 week after
their arrival. Four rats were housed per cage (size 26 
41 cm); animals were fed with standard laboratory diet
and tap water ad libitum, and kept at 23 6 1C with
a 12 hour light/dark cycle, light at 7 a.m. All animal ma-
nipulations were carried out according to the European
Community guidelines for animal care (DL 116/92, appli-
cation of the European Communities Council Directive of
24 November 1986 (86/609/EEC). The ethical policy of the
University of Florence complies with the Guide for the
Care and Use of Laboratory Animals of the US National
Institutes of Health (NIH Publication No. 85-23, revised
1996; University of Florence assurance number: A5278-
01). Formal approval to conduct the experiments de-
scribed was obtained from the Animal Subjects Review
Board of the University of Florence. Animals were anes-
thetized before cervical dislocation. All efforts were
made to minimize animal suffering and to reduce the
number of animals used.
Oxaliplatin Model
Rats were treated with 2.4 mgkg1 oxaliplatin, admin-
istered intraperitoneally (i.p.) for 5 consecutivedaysevery
week for 3 weeks (15 i.p. injections).8 Oxaliplatin was dis-solved in 5% glucose solution. Control animals received
an equivalent volume of 5% glucose i.p. Behavioral and
biochemical tests were performed at the 21st day. The
time course of behavioral measures revealed that pain
began on day 14 but not uniformly in all animals.Drug Treatments
Silibinin (Sigma-Aldrich, Milan, Italy) and a-tocopherol
(Sigma-Aldrich, Milan, Italy) were used at 100 mgkg1.
Both drugs were suspended in 1% carboxymethylcellu-
lose sodium salt (CMC) and administered by the per os
(p.o.) route. Repeated treatment (chronic) consisted of
a daily administration following the same protocol de-
scribed for oxaliplatin from the first up to the 20th day.
Behavioral and biochemical tests were performed 24
hours after the end of treatments. Acute treatment con-
sisted in a single p.o. administration of silibinin and a-to-
copherol (100 mgkg1) at the 21st day of oxaliplatin
injection. Control animals received an equivalent volume
of 1% CMC p.o.Paw Pressure Test
The nociceptive threshold in the rat was determined
with an analgesimeter (Ugo Basile, Varese, Italy), accord-
ing to the method described by Leighton et al.27 Briefly,
a constantly increasing pressure was applied to a small
area of the dorsal surface of the paw using a blunt coni-
cal probe by a mechanical device. Mechanical pressure
was increased until vocalization or a withdrawal reflex
occurred while rats were lightly restrained. Vocalization
orwithdrawal reflex thresholdswere expressed in grams.
Rats scoring below 40 g or over 75 g during the test be-
fore drug administration were rejected (25%). For anal-
gesia measures, mechanical pressure application was
stopped at 120 g. Experiments were performed blind.Von Frey Test
The animals were placed in 20- 20-cmplexiglas boxes
equipped with a metallic meshy floor, 20 cm above the
bench. A habituation of 15 minutes was allowed before
the test. An electronic Von Frey hair unit (Ugo Basile, Var-
ese, Italy) was used: the withdrawal threshold was evalu-
ated by applying force ranging from 0 to 50 grams with
a .2 gram accuracy. Punctuate stimulus was delivered to
the midplantar area of each anterior paw from below
themeshy floor through a plastic tip and the withdrawal
threshold was automatically displayed on the screen.
Paw sensitivity threshold was defined as the minimum
pressure required to elicit a robust and immediate with-
drawal reflex of the paw. Voluntary movements associ-
ated with locomotion were not taken as a withdrawal
response. Stimuli were applied on each anterior paw
with an interval of 5 seconds. The measure was repeated
5 times and the final value was obtained by averaging
the 5 measures.43Cold Plate Test
The animals were placed on a stainless box (12- 20-
10-cm) with a cold plate as floor. The temperature of the
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haviors (ie, lifting and licking of the hind paw) were ob-
served and the time (seconds) of the first sign was
recorded. The cut-off time of the latency of paw lifting
or licking was set at 60 seconds.Rota-Rod Test
Rota-rod apparatus (Ugo Basile, Varese, Italy) con-
sisted of a base platform and a rotating rod with a diam-
eter of 6 cm and a nonslippery surface. The rod was
placed at a height of 25 cm from the base. The rod, 36
cm in length, was divided into 4 equal sections by 5 disks.
Thus, up to 4 rats were tested simultaneously on the ap-
paratus, with a rod-rotating speed of 10 rpm. The integ-
rity of motor coordination was assessed on the basis of
walking time and the number of falls from the rod for
a maximum of 10 minutes (600 seconds). After a maxi-
mum of 6 falls from the rod, test was suspended and
the time was recorded.Tissue Processing
After behavioral tests, animals were sacrificed, blood
was collected in heparin-treated tubes, and plasma frac-
tionwas isolated by centrifugation. The sciatic nerve and
the lumbar portion of spinal cord were isolated, immedi-
ately frosted in liquid nitrogen, and fragmented. Part of
the obtained powder was treated with TRI-Reagent
(Sigma-Aldrich, Milan, Italy) and processed for DNA ex-
traction. The remaining part was homogenized in lysis
buffer containing 50 mM Tris-HCl pH 8.0, 150 mM NaCl,
1 mM EDTA, .5% Triton X-100, Complete Protease Inhib-
itor (Roche), and the homogenate was incubated on ice
for 30 minutes. Then, the suspension was sonicated on
ice using 3, 10-second bursts at high intensity with
a 10-second cooling period between each burst. The ob-
tained material was used for lipid peroxidation assay
and, after centrifugation (13,000 g for 15 minutes at
4C), for Western blot analysis.Lipid Peroxidation (Thiobarbituric Acid
Reactive Substances, TBARS)
Thiobarbituric acid reactive substances (TBARS) were
quantified in plasma and tissue homogenates as
described previously, with some minor modifications.36
100 ml of plasma or 100 mg of tissue homogenate were
added to 4 mL reaction mixture consisting of 36 mM thi-
obarbituric acid (Sigma-Aldrich, Milan, Italy) solubilized
in 10% CH3COOH, .2 % SDS, pH was adjusted to 4.0
with NaOH. The mixture was heated for 60 minutes at
100C and the reaction was stopped by placing the vials
in ice bath for 10 minutes. After centrifugation (at
1,600 g at 4C for 10 minutes) the absorbance of the su-
pernatant was measured at 532 nm (Perkin-Elmer spec-
trometer, Monza, Italy) and TBARS were quantified in
mmoles/milligram of total protein using 1,1,3,3-
tetramethoxypropane as standard. Protein homogenate
concentration was measured by bicinchoninc acid (BCA;
Sigma-Aldrich, Milan, Italy) assay.Carbonylated Protein Evaluation
Carbonylated proteins were evaluated in tissue
homogenates (see previous paragraph) and plasma.
Plasma or nervous tissue proteins extract were quanti-
fied by BCA. Twenty mg of each sample were denatured
by 6% SDS and derivatized by 15-minute incubation
with 2-4 dinitrophenyl hydrazine (DNPH; Sigma-
Aldrich, Italy) at room temperature. Samples were
separated on a 4–12% sodium dodecyl sulfate (SDS)-
polyacrylamide gel by electrophoresis and transferred
onto nitrocellulose membranes (Biorad, Italy). Mem-
branes were blocked with 5% nonfat dry milk in
phosphate-buffered saline (PBS) containing .1% Tween
20 (PBST) and then probed overnight with primary anti-
body specific versus DNPH (Sigma-Aldrich, Italy) 1:5000 in
PBST/5% nonfat dry milk. After washing with PBST, the
membranes were incubated for 1 hour in PBST contain-
ing the appropriate horseradish peroxidase-conjugated
secondary antibody (1:5000; Cell Signalling, USA) and
again washed. ECL (Pierce, USA) was used to visualize
the peroxidase-coated bands. Densitometric analysis
was performed using the ‘‘Scion Image’’ analysis soft-
ware. For each experiment the density of all bands
showed in a lane was reported as mean. For plasma sam-
ples Ponceau-stained membranes were used as loading
control. b-actin normalization was performed for ner-
vous tissue samples.13
DNA Oxidation
One hundred mg DNA for each sample were digested
for 2 hours (37C) in 25 mM CH3COONa buffer, pH 4.8,
containing 1 mM ZnCl2 and 1.1 units of nuclease P1
(Sigma-Aldrich, Milan, Italy). pH was then adjusted to
8.0 using Tris 1.5 M. One unit of alkaline phosphatase
(Sigma-Aldrich, Italy) was added and incubated at 37C
for 30 minutes. Samples were boiled for 10 minutes
and 8-OH-dG levels were measured in a volume contain-
ing 30 mg of initial DNA by ELISA assay (Cayman, Ann
Arbor, MI). Measures were performed in triplicate. The
absorbance was measured at 420 nm (Perkin-Elmer spec-
trometer, Monza, Italy) according to manufacturing in-
structions. The level of DNA oxidation was expressed as
pg/mL of 8-OH-dG.
Statistic Analysis
Results were expressed asmeans6 S.E.M. and the anal-
ysis of variance was performed by analysis of variance. A
Bonferroni’s significant difference procedure was used
as post hoc comparison. P values of less than .05 or .01
were considered significant. Data were analyzed using
the ‘‘Origin 8.1’’ software.Results
Intraperitoneal daily administration of oxaliplatin
(2.4 mgkg1) induced a neuropathy characterized by
pain starting from the 14th day (data not shown). On
the 21st day, the response to a noxious mechanical
stimulus was increased and reached the maximum: the
pressure tolerated on the posterior paw, measured by
Figure 1. Pain: noxious stimulus, Paw-pressure test. Rats were
daily intraperitoneally treated with 2.4 mgkg1 oxaliplatin (dis-
solved in 5% glucose). Hyperalgesia was evaluated at day 21 by
Paw-pressure test. Silibinin or a-tocopherol (100 mgkg1, dis-
solved in CMC) were per os administered acutely (single injec-
tion 30 minutes before the test; acute) or repetitively (daily for
20 days starting from the first day of oxaliplatin administration;
chronic). Control animals were treated with vehicles. Each value
represents the mean of 24 rats per group, performed in 2 differ-
ent experimental sets. *P < .01 versus CMC 1 glucose (control).
^P < .01 versus CMC-oxaliplatin.
Figure 2. Pain: non-noxious stimuli. (A) Von Frey test was used
to measure the response evoked by a mechanical stimulus. (B)
The response to a thermal stimulus was evaluated by cold plate
test measuring the latency (seconds) to pain-related behaviors
(lifting or licking of the paw). Rats were daily intraperitoneally
treated with 2.4 mgkg1 oxaliplatin (dissolved in 5% glucose).
Behavior was evaluated at day 21. Silibinin or a-tocopherol
(100 mgkg1, dissolved in CMC) were per os administered
acutely (single injection 30 minutes before the test; acute) or re-
petitively (daily for 20 days starting from the first day of oxali-
platin administration; chronic). Control animals were treated
with vehicles. Each value represents the mean of 24 rats per
group, performed in 2 different experimental set. *P < .01 versus
CMC 1 glucose (control). ^P < .01 versus CMC-oxaliplatin.
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trol value of 69.2 6 1.7 g (Fig 1, CMC 1 glucose) to 38.4
6 2.8 g for the oxaliplatin-treated animals (CMC 1
oxaliplatin). Silibinin- and a-tocopherol-treated animals
(100 mgkg1 p.o. administered daily from day 1 to day
20) showed a significant lower responsiveness to a nox-
ious stimulus (57.3 6 1.6 g and 58.4 6 2.1 g, respec-
tively; Fig 1, chronic) in respect to the oxaliplatin
group. Both molecules were ineffective when adminis-
tered once, 30 minutes before test (Fig 1, acute). More-
over, oxaliplatin induced a lowered threshold to
mechanical and cold stimuli which do not normally
provoke pain (Figs 2A and 2B). As measured with the
electronic Von Frey apparatus, control withdrawal
threshold to the non-noxious mechanical stimulus was
decreased in oxaliplatin treated animals from 28.2 6
1.1 g to 14.9 6 1.6 g (Fig 2A). Repeated silibinin admin-
istration partially modified pain threshold increasing
the tolerated pressure on the anterior paw up to 19.9
6 .9 g. A comparable effect was induced by a-tocoph-
erol (Fig 2A, chronic). The sensibility to a cold surface
is depicted in Fig 2B. After oxaliplatin treatment, the
licking latency decreased from 25.1 6 1.1 seconds
(CMC 1 glucose) to 14.2 6 .4 seconds (CMC 1 oxalipla-
tin). Both antioxidants significantly prevented cold
hypersensibility (silibinin: 19.4 6 .5 seconds; a-tocoph-
erol: 19.7 6 .2 seconds). In both Von Frey and cold plate
test, silibilin and a-tocopherol acutely administered
before test were ineffective. Chemotherapy-induced
neuropathy impaired motor coordination as evaluated
by the walking time on a rotating rod and the number
of falls (Rota-rod test). Indeed, control rats were able to
balance on the rotating rod for 600 seconds (Fig 3), fall-
ing down .6 6 .1 folds. On the contrary, oxaliplatin-treated animals maintained the balance for 163 6 67
seconds only and fell down 4.9 6 .2 times. Silibinin
and a-tocopherol improved the time of walking up to
415 6 64 seconds and 409 6 80 seconds respectively
(Fig 3, chronic) but they were ineffective on the number
of falls. Again, antioxidant acute treatment was ineffec-
tive (Fig 3, acute).
Aimed to evaluate the oxidative stress after the oxali-
platin administration, rat plasma samples were analyzed
at the 21st day to measure TBARS and protein carbonyl-
ation. In plasma of oxaliplatin treated rats, lipid peroxi-
dation was significantly increased as compared with
control animals (CMC 1 glucose). The increase in TBARS
induced by oxaliplatin treatment was fully prevented
by silibinin and a-tocopherol repeated treatment
(Fig 4A).
Figure 3. Motor coordination in oxaliplatin-treated rats. The
integrity of the animals’ motor coordination was assessed using
a rota-rod apparatus. Rats were placed on a rotating rod (10
rpm) for amaximumof 10minutes (600 seconds). The time spent
in the balance was counted. Rats were daily intraperitoneally
treated with 2.4 mgkg1 oxaliplatin (dissolved in 5% glucose).
Motor coordination was evaluated at day 21. Silibinin or a-to-
copherol (100 mgkg1, dissolved in CMC) were per os adminis-
tered acutely (single injection 30 minutes before the test;
acute) or repetitively (daily for 20 days starting from the first
day of oxaliplatin administration; chronic). Control animals
were treated with vehicles. Each value represents the mean of
24 rats per group, performed in 2 different experimental set.
*P < .01 versus CMC 1 glucose (control). ^P < .01 versus CMC-
oxaliplatin.
Figure 4. Plasma oxidation levels in rats treated with oxalipla-
tin. At day 21, plasma was collected and oxidative stress evalu-
ated. (A) Lipid peroxidation was evaluated measuring TBARS
levels. (B) Protein oxidative damage was measured quantifying
carbonylated proteins by immunoblot. Densitometric analysis
(top panel) and representative Western blot (lower panel) are
shown. Ponceau-stained membranes were used as loading con-
trol. Silibinin or a-tocopherol (100 mgkg1, dissolved in CMC)
were per os repetitively administered (daily for 20 days starting
from the first day of oxaliplatin administration). Control animals
were treatedwith vehicles. Each value represents themean of 12
rats pergroup,performed in2different experimental set. *P< .01
versus CMC1 glucose (control). ^P < .01 versus CMC-oxaliplatin.
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oxaliplatin-treated rats than in control animals (Fig 4B).
Protein oxidation was prevented by 81 and 58% by silibi-
nin and a-tocopherol, respectively (Fig 4B).
The study of the oxidative damage evoked by oxalipla-
tin was extended to the nervous system, final target of
chemotherapy toxicity. Both peripheral and central ner-
vous system of 21 day-treated rats showed an increase
in lipid peroxidation as reported in Fig 5A. Sciatic nerve
TBARS levels increased in the oxaliplatin group from
38.4 6 5.3 to 57.6 6 3.0 mmol/mg proteins (Fig 5A, left
panel) and in spinal cord from 94.7 6 12.2 to 179.8 6
24.3 (Fig 5A, right panel). Antioxidants exerted a preven-
tive effect of about 80% in the sciatic nerve and 70% in
the spinal cord. Moreover, oxidative stress at protein
level was highlighted in both sciatic nerve and spinal
cord of oxaliplatin-treated animals by a 3 increase in
carbonylated level in respect to control. Silibinin and
a-tocopherol inhibited protein oxidation by about 60%
(Fig 5B).
Finally, DNA oxidation was evaluated in nervous tis-
sue. In the sciatic nerve, the basal level of 8-OH-dG
was 3.2 6 2.3 pg/mL (CMC 1 glucose). Oxaliplatin in-
creased this value up to 38.6 6 8.3 pg/mL; silibinin
and a-tocopherol decreased oxaliplatin-induced DNA
oxidation by 48% and by 63% respectively (Fig 6, left
panel). Also in the spinal cord, oxaliplatin increased 8-
OH-dG from 8.7 6 2.2 pg/mL (CMC 1 glucose) to 52.8
6 4.3 pg/mL (CMC 1 oxaliplatin); silibinin and a-tocoph-
erol prevented 8-OH-dG formation by 65 and 76% re-
spectively (Fig 6, right panel).Discussion
The clinical treatment of chemotherapy-induced
neuropathy is based on symptomatic drugs. However,
in addition to the possibility of side effects, their
Figure 5. Nervous tissue oxidation levels in rats treated with oxaliplatin. At 21st day, the sciatic nerve and the lumbar tract of the
spinal cord were explanted. Peripheral and central nervous tissues were analyzed for both lipid and protein oxidation. (A) TBARS
levels in sciatic nerve (left panel) and in spinal cord (right panel). (B) Carbonylated protein in sciatic nerve (left panel) and in spinal
cord (right panel). Densitometric analysis (top panel) and representativeWestern blot (lower panel) are shown. b-actin normalization
was performed for each sample. Silibinin or a-tocopherol (100 mgkg1, dissolved in CMC) were per os repetitively administered (daily
for 20 days starting from the first day of oxaliplatin administration). Control animalswere treatedwith vehicles. Each value represents
themeanof 12 rats per group, performed in 2 different experimental set. *P < .01 versus CMC1 glucose (control). ^P < .01 versus CMC-
oxaliplatin.
Di Cesare Mannelli et al The Journal of Pain 281effectiveness in the treatment of painful neuropathy
is not yet definitely proven.2,20,24 Therefore, the
development of active disease-modifying agents is the
goal of the research in this field. This issue is hampered
by the insufficient knowledge of damage mechanisms.
The present data show that in the in vivo model of
oxaliplatin-induced neuropathy, oxidative stress is ob-
served at lipid, protein, and DNA levels both in plasma
as well as in the nervous system. Lipid peroxidation is
a well-established mechanism of cellular injury in
both plants and animals and it is used as an indicator
of oxidative stress. TBARS are naturally occurring
products of lipid peroxidation that are increased by
oxidative stress.36 Oxidative modification of proteins
by ROS and other high reactive molecules such as hy-droxynonenal occurs in physiologic and pathologic
processes. As a consequence of the modification, car-
bonyl groups are introduced into protein side chains
by a site-specific mechanism,13 inducing decreased
functionality. Finally, at the DNA level, hydroxylation
of guanosine occurs in response to both normal
metabolic processes and a variety of environmental fac-
tors. Increased levels of 8-OH-dG are associated with
the aging process as well as with a number of patho-
logical conditions including cancer, diabetes, and
hypertension.28,45
Oxaliplatin neurotoxicity is described to be localized at
dorsal root ganglia level.47 As reported by Jacobs
et al22,23 after a single administration by i.v. injection
(5 mgkg1 i.v.) in nonhuman primates, the oxaliplatin
Figure 6. DNA oxidation levels in nervous tissue of oxaliplatin-treated rats. DNAwas extracted from sciatic nerve and spinal cord of
treated animals at day 21. DNA samples were analyzed by ELISA method to quantify 8-OH-2-dG levels. Silibinin or a-tocopherol (100
mgkg1, dissolved in CMC) were per os repetitively administered (daily for 20 days starting from the first day of oxaliplatin adminis-
tration). Control animals were treated with vehicles. Each value represents the mean of 12 rats per group, performed in 2 different
experimental sets. *P < .01 versus CMC 1 glucose (control). ^P < .01 versus CMC-oxaliplatin.
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oxidative damage is here described also in the spinal
cord. On the other hand, data about the oxaliplatin
concentration in the central nervous system after
repeated administration are lacking.
After a repeated treatment during oxaliplatin adminis-
tration, antioxidant dosage (100 mgkg1)19,32,49,50 of
silibinin and a-tocopherol show a comparable efficacy
as antihyperalgesic agents. On the contrary, acute
administration of both molecules are ineffective. These
results exclude a symptomatic analgesic effect of
antioxidant compounds.
Moreover, a concomitant, significant decrease of the
oxaliplatin-induced oxidative state is shown in plasma
and in the nervous system of rats repetitively treated
with silibilin and a-tocopherol.
The results lead us to hypothesize about a relation-
ship between the preventive activity against oxidative
stress and the anti-hyperalgesic properties of both
molecules.
Clinically used antioxidant agents partially reduce
oxaliplatin-induced toxicitywithout a precise explanation
for their limited, beneficial effects.7,29,38 It remains to be
seen if their therapeutic limited effectiveness is due to
the scarce activity of the presently available substances
or to the complexity of oxaliplatin neurotoxicity where
oxidative stress could be only an epiphenomenon.
On the other hand, the mechanism by which oxalipla-
tin provokes ROS increase is not completely established
and it could be due to a characteristic cell damage. A mi-
tochondrial alteration has been suggested as a mecha-
nism of oxaliplatin-mediated oxidation.51 Moreover,
dynamin-related protein 1, a protein that catalyzes the
process of mitochondrial fission with the consequent
ROS production, is involved in chemotherapy-induced
neuropathy in rats.16 By contrast, a low relevance of
ROS production from inflammatory cells could be hy-
pothesized since another side effect related to pro-
longed oxaliplatin use is a nonmyelosuppressivehematologic toxicity, which includes hemolysis,18 throm-
bocytopenia,5 and pancytopenia.48
It is of fundamental importance that, to be clinically
useful, the antineuropathic agents must reduce the neu-
rotoxic effect of the chemotherapeutic agentmaintaining
its full anti-tumor efficacy. In this light, silibinin shows
a cancer chemopreventive role in both in vitro10,21 and
in vivo40,46 models. It modulates the imbalance between
cell survival and apoptosis through interference with the
expressions of cell cycle regulators and proteins involved
in apoptosis.26 In addition, an anti-metastatic activity for
silibinin has been also described.11,21 A recent report of
the USA National Toxicology Program33 describes the
results of repeated treatments of rats with sylibummaria-
numextract (containing 65%sylimarin, therefore 30–40%
silibinin).1No toxic effects havebeen shownafter daily per
os administration of 2,500 mgkg1 extract for 2 years.
Moreover, there is no evidence of carcinogenic activity
whereas the incidences of mammary gland neoplasms
and hepatocellular neoplasms are decreased. In this
view, silibinin should not interfere with the anticancer
property of oxaliplatin.41
The present data highlight the anti-neuropathic prop-
erties of silibinin which, together with its protective
effects in hepatic diseases15,30,31,44 as well as in
neurodegenerative disorders,31 suggest its clinical appli-
cability as an adjuvant in cancer patients to prevent or
reduce chemotherapy-induced toxicity. The protective
effects and the anticancer activity confer to silibinin
a ubiquitous profile that differentiates this molecule
from other antioxidant drugs clinically used to treat
oxaliplatin-induced neuropathic pain.
Moreover, according to our results, oxidative stress is
an important target in oxaliplatin-dependent neuro-
pathic pain and allows us to identify a mechanism of
oxaliplatin-induced neurotoxicity. Finally, the research
of fully active antioxidant compounds remains an attrac-
tive therapeutic perspective to treat neuropathy through
neurorestorative effects.
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